Ketorolac 0.45% ophthalmic solution

Drugs and Aging

Volumn 28, Issue 7, 2011, Pages 583-589

  McCormack, Paul L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Ketorolac; Ocular inflammation; Ocular pain; Ophthalmic

Indexed keywords

ACUVAIL; AMFENAC; BROMFENAC; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GATIFLOXACIN; KETOROLAC; NEPAFENAC; PARACETAMOL; PLACEBO; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANTERIOR EYE CHAMBER CELL; ANTERIOR EYE CHAMBER DISEASE; ANTERIOR EYE CHAMBER FLARE; ANTERIOR EYE CHAMBER INFLAMMATION; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLURRED VISION; CATARACT EXTRACTION; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CORNEA EDEMA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG PENETRATION; DRUG TOLERABILITY; ENZYME INHIBITION; EPIPHORA; EYE BURNING; EYE INFLAMMATION; EYE PAIN; EYELID EDEMA; FACE PAIN; FOREIGN BODY; HUMAN; INTRAOCULAR PRESSURE; IRITIS; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHACOEMULSIFICATION; PHOTOPHOBIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RABBIT; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UVEITIS; VISUAL ACUITY; WOUND HEALING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; KETOROLAC; OPHTHALMIC SOLUTIONS;

EID: 79959984438     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11207450-000000000-00000     Document Type: Article

References (21)

1. Simone JN, Pendelton RA, Jenkins JE. Comparison of the efficacy and safety of ketorolac tromethamine 0.5% and prednisolone acetate 1% after cataract surgery. J Cataract Refractive Surg 1999; 25 (5): 699-704 (Pubitemid 29222602)
2. Colin J. The role of NSAIDs in the management of postoperative ophthalmic inflammation. Drugs 2007; 67 (9): 1291-308 (Pubitemid 46879095)
3. Simone JN, Whitacre MM. Effects of anti-inflammatory drugs following cataract extraction. Curr Opin Ophthalmol 2001 Feb; 12 (1): 63-7 (Pubitemid 32113614)
4. OBrien TP. Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care. Curr Med Res Opin 2005 Jul; 21 (7): 1131-7
5. Perry HD, Donnenfeld ED. An update on the use of ophthalmic ketorolac tromethamine 0.4%. Expert Opin Pharmacother 2006; 7 (1): 99-107 (Pubitemid 43056426)
6. Flach AJ, Dolan BJ, Donahue ME, et al. Comparative effects of ketorolac 0.5% or diclofenac 0.1% ophthalmic solutions on inflammation after cataract surgery. Ophthalmology 1998; 105 (9): 1775-9 (Pubitemid 28513535)
7. Holzer MP, Solomon KD, Sandoval HP, et al. Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study. J Cataract Refractive Surg 2002; 28 (1): 93-9 (Pubitemid 34052016)
8. Duong H-VQ, Westfield KC, Chalkley THF. Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery: prospective randomized doublemasked clinical trial. J Cataract Refractive Surg 2007; 33 (11): 1925-9 (Pubitemid 47628809)
9. Maca SM, Amon M, Findl O, et al. Efficacy and tolerability of preservative-free and preserved diclofenac and preserved ketorolac eyedrops after cataract surgery. Am J Ophthalmol 2010 May; 149 (5): 777-84
10. US FDA. ACULAR- (ketorolac tromethamine ophthalmic solution) 0.5%: US prescribing information [online]. Available from URL: http://www.accessdata.fda. gov/drugsatf da-docs/label/2005/19700S023,024lbl.pdf [Accessed 2011 Jun 10]
11. Allergan Inc. ACULAR LS- (ketorolac tromethamine ophthalmic solution) 0.4%: US prescribing information [online]. Available from URL: http://www.allergan.com/ assets/pdf/acular-ls-pi.pdf [Accessed 2011 Jun 10]
12. Allergan Inc. ACUVAIL (ketorolac tromethamine ophthalmic solution) 0.45%: US prescribing information [online]. Available from URL: http://www.allergan. com/assets/ pdf/acuvail-pi.pdf [Accessed 2011 Jun 10]
13. Donnenfeld ED, Nichamin LD, Hardten DR, et al. Twicedaily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery. Am J Ophthalmol 2011 Mar; 151 (3): 420-6
14. Gillis JC, BrogdenRN.Ketorolac: a reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs 1997; 53 (1): 139-88 (Pubitemid 27045700)
15. Sandoval HP, Fernandez de Castro LE, Vroman DT, et al. A review of the use of ketorolac tromethamine 0.4% in the treatment of post-surgical inflammation following cataract and refractive surgery. Clin Ophthalmol 2007 Dec; 1 (4): 367-71
16. Waterbury LD, Galindo D, Villanueva L, et al. Ocular penetration and anti-inflammatory activity of ketorolac 0.45% and bromfenac 0.09% against lipopolysaccharideinduced inflammation. J Ocul Pharmacol Ther 2011 Apr; 27 (2): 173-8
17. Xu K, McDermott M, Villanueva L, et al. Ex vivo corneal epithelial wound healing following exposure to ophthalmic nonsteroidal anti-inflammatory drugs. Clin Ophthalmol 2011 Feb; 5: 269-74
18. Bucci FA Jr, Waterbury LD, Evans R, et al. PGE2 inhibition of ketorolac 0.45% (Acuvail) vs. bromfenac 0.09% (Xibrom) with trough dosing in patients undergoing phacoemulsification [abstract no. PO310]. American Academy of Ophthalmology 2010 Joint Meeting; 2010 Oct 16-19; Chicago (IL
19. Attar M, Schiffman R, Borbridge L, et al. Ocular pharmacokinetics of 0.45% ketorolac tromethamine. Clin Ophthalmol 2010; 4: 1403-8
20. Amico LM, Bucci FA Jr, Evans R, et al. Aqueous penetration of ketorolac tromethamine 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification [abstract no. D1052]. Invest Ophthalmol Vis Sci 2010; 51: E-Abstract 2456
21. Center for Drug Evaluation and Research. Acuvail (ketorolac tromethamine ophthalmic solution) 0.45%: medical review [online]. Available from URL: http://www.access data.fda.gov/drugsatfda-docs/nda/2009/022427s000-Med R.pdf [Accessed 2011 Jun 10]